JP4355142B2 - 組換え法 - Google Patents
組換え法 Download PDFInfo
- Publication number
- JP4355142B2 JP4355142B2 JP2002563325A JP2002563325A JP4355142B2 JP 4355142 B2 JP4355142 B2 JP 4355142B2 JP 2002563325 A JP2002563325 A JP 2002563325A JP 2002563325 A JP2002563325 A JP 2002563325A JP 4355142 B2 JP4355142 B2 JP 4355142B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- recombination
- protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000006798 recombination Effects 0.000 title claims description 211
- 238000005215 recombination Methods 0.000 title claims description 211
- 238000000034 method Methods 0.000 title claims description 144
- 150000007523 nucleic acids Chemical class 0.000 claims description 210
- 102000039446 nucleic acids Human genes 0.000 claims description 205
- 108020004707 nucleic acids Proteins 0.000 claims description 205
- 108090000623 proteins and genes Proteins 0.000 claims description 197
- 102000004169 proteins and genes Human genes 0.000 claims description 152
- 108091034117 Oligonucleotide Proteins 0.000 claims description 141
- 210000004027 cell Anatomy 0.000 claims description 141
- 238000000137 annealing Methods 0.000 claims description 112
- 108020004414 DNA Proteins 0.000 claims description 101
- 239000013612 plasmid Substances 0.000 claims description 83
- 230000008439 repair process Effects 0.000 claims description 62
- 102000053602 DNA Human genes 0.000 claims description 56
- 101100316841 Escherichia phage lambda bet gene Proteins 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 239000002773 nucleotide Substances 0.000 claims description 40
- 210000000349 chromosome Anatomy 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 241000894007 species Species 0.000 claims description 23
- 238000004520 electroporation Methods 0.000 claims description 22
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 18
- 101100226347 Escherichia phage lambda exo gene Proteins 0.000 claims description 17
- 102000001218 Rec A Recombinases Human genes 0.000 claims description 16
- 108010055016 Rec A Recombinases Proteins 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 238000010367 cloning Methods 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 238000006011 modification reaction Methods 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000011426 transformation method Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000219194 Arabidopsis Species 0.000 claims description 2
- 241000203069 Archaea Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 102000035118 modified proteins Human genes 0.000 claims description 2
- 108091005573 modified proteins Proteins 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 241001646716 Escherichia coli K-12 Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000018427 Iphisa elegans Species 0.000 claims 1
- -1 RecT (rac prophage) Proteins 0.000 claims 1
- 230000013120 recombinational repair Effects 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 53
- 241001045988 Neogene Species 0.000 description 46
- 101150091879 neo gene Proteins 0.000 description 46
- 230000000694 effects Effects 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 38
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 31
- 239000012634 fragment Substances 0.000 description 29
- 229960000318 kanamycin Drugs 0.000 description 28
- 229930027917 kanamycin Natural products 0.000 description 27
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 27
- 229930182823 kanamycin A Natural products 0.000 description 27
- 230000037361 pathway Effects 0.000 description 20
- 238000002744 homologous recombination Methods 0.000 description 19
- 230000006801 homologous recombination Effects 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 16
- 230000002950 deficient Effects 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 229960000723 ampicillin Drugs 0.000 description 15
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 15
- 230000035772 mutation Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 229960005091 chloramphenicol Drugs 0.000 description 12
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 108700010839 phage proteins Proteins 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000012552 review Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 238000010606 normalization Methods 0.000 description 8
- 241000206602 Eukaryota Species 0.000 description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000010187 selection method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 101150098466 rpsL gene Proteins 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108060002716 Exonuclease Proteins 0.000 description 5
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 102000013165 exonuclease Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 101150066555 lacZ gene Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101100342379 Mus musculus Kmt2a gene Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 210000000688 human artificial chromosome Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 2
- 230000008836 DNA modification Effects 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 2
- 108010025076 Holoenzymes Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 101150049515 bla gene Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 101150087770 recT gene Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150033922 ABCA2 gene Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150094177 Erf gene Proteins 0.000 description 1
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 1
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101150006234 RAD52 gene Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 description 1
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 description 1
- 101100437728 Rattus norvegicus Bloc1s2 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000701835 Salmonella virus P22 Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000338168 Tringa Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011259 co-electroporation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Landscapes
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0103276A GB0103276D0 (en) | 2001-02-09 | 2001-02-09 | Recombination method |
| GB0120312A GB0120312D0 (en) | 2001-08-21 | 2001-08-21 | Recombination method |
| PCT/IB2002/001415 WO2002062988A2 (en) | 2001-02-09 | 2002-02-08 | Recombination method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004535773A JP2004535773A (ja) | 2004-12-02 |
| JP2004535773A5 JP2004535773A5 (enExample) | 2008-06-05 |
| JP4355142B2 true JP4355142B2 (ja) | 2009-10-28 |
Family
ID=26245704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563325A Expired - Fee Related JP4355142B2 (ja) | 2001-02-09 | 2002-02-08 | 組換え法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040101520A1 (enExample) |
| EP (1) | EP1399546A2 (enExample) |
| JP (1) | JP4355142B2 (enExample) |
| CA (1) | CA2436743A1 (enExample) |
| WO (1) | WO2002062988A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1311661T3 (da) | 2000-08-14 | 2012-11-26 | Us Gov Health & Human Serv | Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner |
| US7521242B2 (en) | 2003-05-09 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids |
| US7674621B2 (en) | 2004-05-21 | 2010-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Plasmids and phages for homologous recombination and methods of use |
| US20070281309A1 (en) * | 2006-05-19 | 2007-12-06 | Massachusetts Institute Of Technology | Microfluidic-based Gene Synthesis |
| GB0909660D0 (en) | 2009-06-04 | 2009-07-22 | Gene Bridges Gmbh | Method of altering nucleic acids |
| GB0922108D0 (en) | 2009-12-17 | 2010-02-03 | Gene Bridges Gmbh | Heterologous hosts |
| GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| CN103667331B (zh) * | 2013-12-10 | 2015-09-30 | 南京师范大学 | 重组酶基因bet作为一种大肠杆菌异源蛋白表达融合标签的应用 |
| JP6899564B2 (ja) * | 2016-08-12 | 2021-07-07 | Ｎｅｘｕｓｐｉｒａｌ株式会社 | ゲノム編集方法 |
| CN106995813B (zh) | 2017-03-23 | 2020-06-16 | 山东大学 | 基因组大片段直接克隆和dna多分子组装新技术 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE449844T1 (de) * | 1997-12-05 | 2009-12-15 | Europ Lab Molekularbiolog | Neue methode zur klonierung dns unter anwendung des e. coli rece/rect rekombinationssystems |
| DK1311661T3 (da) * | 2000-08-14 | 2012-11-26 | Us Gov Health & Human Serv | Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner |
-
2002
- 2002-02-08 EP EP02722618A patent/EP1399546A2/en not_active Withdrawn
- 2002-02-08 US US10/470,679 patent/US20040101520A1/en not_active Abandoned
- 2002-02-08 WO PCT/IB2002/001415 patent/WO2002062988A2/en not_active Ceased
- 2002-02-08 CA CA002436743A patent/CA2436743A1/en not_active Abandoned
- 2002-02-08 JP JP2002563325A patent/JP4355142B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004535773A (ja) | 2004-12-02 |
| CA2436743A1 (en) | 2002-08-15 |
| EP1399546A2 (en) | 2004-03-24 |
| WO2002062988A2 (en) | 2002-08-15 |
| WO2002062988A3 (en) | 2004-01-15 |
| US20040101520A1 (en) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034562A1 (en) | Compositions and methods for improving the efficacy of cas9-based knock-in strategies | |
| JP7301332B2 (ja) | Ｄｎａが編集された真核細胞を製造する方法、および当該方法に用いられるキット | |
| Murphy | λ recombination and recombineering | |
| CN106995813B (zh) | 基因组大片段直接克隆和dna多分子组装新技术 | |
| CN103068995B (zh) | 直接克隆 | |
| CN100357427C (zh) | 利用多识别位点合成核酸分子的方法和组合物 | |
| JP2019526248A (ja) | プログラム可能ｃａｓ９−リコンビナーゼ融合タンパク質およびその使用 | |
| JPH11507236A (ja) | 操作された組換え部位を使用する組換えクローニング | |
| CN102027112B (zh) | 核酸重组方法 | |
| JP4355142B2 (ja) | 組換え法 | |
| Penewit et al. | Genome editing in Staphylococcus aureus by conditional recombineering and CRISPR/Cas9-mediated counterselection | |
| JP2004535773A5 (enExample) | ||
| AU2002253479A1 (en) | Recombination method | |
| AU2008202476A1 (en) | Recombination method | |
| González Linares | A CRISPR-associated transposase presents null cargo integration efficiency when targeting a transcriptionally highly active region | |
| WO2010140066A2 (en) | Method of altering nucleic acids | |
| Brumos et al. | An improved plant toolset for high-throughput recombineering | |
| Stoltzfus | Characteristics of enzymes and cloning vectors used to create recombinant DNA | |
| Casini | Better safe than sorry: new CRISPR/Cas9 tools for improved genome engineering | |
| HK40021189B (zh) | Dna被编辑了的真核细胞的制造方法、和在该方法中使用的试剂盒 | |
| Heil | Bacterial chromosome engineering for applications in metabolic engineering | |
| de Las Heras et al. | Genetic constructs: Molecular tools for the assembly of environmental bacterial biosensors | |
| HK40021189A (en) | Method for manufacturing dna-edited eukaryotic cell, and kit used in method | |
| Lou | Transposable prophage Mu exists as an independent chromosomal domain in E. coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080205 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080307 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080314 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090622 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090715 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090731 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120807 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |